ArticleDiabetologia2026
Subtypes of newly diagnosed type 2 diabetes and risk of complications: analysis of electronic health records in the USA.
Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aims/hypothesisData-driven subtyping of type 2 diabetes has not been translated into clinical practice due to the lack of routine fasting glucose and insulin measurements. We aimed to identify type 2 diabetes subtypes in clinical settings using electronic health records and study their epidemiology.
methodsWe identified 727,076 adults (≥18 years) with newly diagnosed type 2 diabetes from Epic Cosmos research platform data across all 50 states and the District of Columbia between 2012 and 2023. Classification models developed in cohort studies were applied to study the sociodemographic distribution of subtypes. Cox proportional hazards regression models, adjusted for age and sex, were used to assess the rates of microvascular complications (retinopathy, neuropathy and nephropathy) and macrovascular complications (severe atherosclerotic cardiovascular disease [ASCVD], other ASCVD and heart failure).
resultsAmong newly diagnosed individuals (mean age 64.4 years [SD 13.3], 52% female), 21.6% were classified as having severe insulin-deficient diabetes (SIDD), 23.8% were classified as having mild obesity-related diabetes (MOD), 40.9% were classified as having mild age-related diabetes and 13.7% were classified as having the mixed subtype. Compared with those classified as having MOD, individuals classified as having SIDD had higher HRs for retinopathy (HR 2.83; 95% CI 2.73, 2.93), neuropathy (HR 1.57; 95% CI 1.54, 1.60), nephropathy (HR 1.34; 95% CI 1.32, 1.37), severe ASCVD (HR 1.49; 95% CI 1.46, 1.53), other ASCVD (HR 1.23; 95% CI 1.21, 1.25) and heart failure (HR 1.17; 95% CI 1.15, 1.20). SIDD and MOD were more prevalent among Hispanics (28.4% and 30.1%, respectively) and non-Hispanic Black people (25.5% and 30.0%, respectively) compared with non-Hispanic White people (20.1% and 21.6%, respectively), and were also more prevalent in the District of Columbia and Utah, respectively, compared with the rest of the country. CONCLUSIONS/
interpretationIndividuals with different type 2 diabetes subtypes, identified through electronic health records, differ in terms of their risk of vascular complications. These findings support leveraging routine electronic health record data to improve the characterisation of patient heterogeneity at the time of diabetes diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.